CP-4126: Phase II started

The partners began an open-label, international Phase II trial (CO-101-001) in 250 patients to compare 1250 mg/m 2 IV CP-4126 weekly for 3 out of every 4 weeks vs. 1000 mg/m 2 IV gemcitabine. Clavis g...